C12Q 1/025
For testing or evaluating the effect of chemical or biological compounds
Official title: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics (antimicrobial activity C12Q1/18)}
C12Q1/025 (For testing or evaluating the effect of chemical or biological compounds) appears on 790 US grants and 1,166 published applications in this corpus.
Search patents in C12Q- Granted patents
- 790
- Published applications
- 1,166
- Assignees
- 730
- Inventors
- 2,672
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 2 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 4 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 3 | 0 |
| 1991 | 1 | 0 |
| 1992 | 4 | 0 |
| 1993 | 4 | 0 |
| 1994 | 6 | 0 |
| 1995 | 5 | 0 |
| 1996 | 6 | 0 |
| 1997 | 17 | 0 |
| 1998 | 20 | 0 |
| 1999 | 18 | 0 |
| 2000 | 8 | 0 |
| 2001 | 13 | 5 |
| 2002 | 14 | 21 |
| 2003 | 10 | 46 |
| 2004 | 9 | 32 |
| 2005 | 15 | 33 |
| 2006 | 16 | 33 |
| 2007 | 12 | 18 |
| 2008 | 14 | 32 |
| 2009 | 15 | 25 |
| 2010 | 11 | 44 |
| 2011 | 15 | 33 |
| 2012 | 29 | 35 |
| 2013 | 33 | 140 |
| 2014 | 40 | 57 |
| 2015 | 48 | 43 |
| 2016 | 49 | 56 |
| 2017 | 27 | 45 |
| 2018 | 33 | 75 |
| 2019 | 29 | 135 |
| 2020 | 46 | 54 |
| 2021 | 60 | 51 |
| 2022 | 50 | 44 |
| 2023 | 32 | 38 |
| 2024 | 37 | 21 |
| 2025 | 20 | 33 |
| 2026 | 11 | 17 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Composition and method for inhibiting BORC complex to treat cancers with NF1 deficiency and dysregulated RAS signaling29 Sep 2026US 12,748,101 B2Trustees of Dartmouth College
- Quantitative screen for the assessment of inter-individual variability in drug metabolism by the human gut microbiome28 Jul 2026US 12,692,529 B2The Trustees of Princeton University
- Amino acid- , peptide- and polypeptide-lipids, isomers, compositions, and uses thereof9 Jun 2026US 12,648,959 B2Massachusetts Institute of Technology
- Rapid evaporative ionisation mass spectrometry (“REIMS”) and desorption electrospray ionisation mass spectrometry (“DESI-MS”) analysis of swabs and biopsy samples2 Jun 2026US 12,646,702 B2Micromass UK Limited
- Identification of host-targeting modulators of bacterial uptake and assay for quantifying intracellular bacteria19 May 2026US 12,630,856 B2University of Florida Research Foundation, Inc.
- Replicon dna, cloning vector, screening kit, screening method, anti-nobecov-irus agent, beta-coronavirus proliferation inhibitor, pan beta-coronavirus inhibitor, virus proliferation inhibitor, hepatitis c virus proliferation inhibitor, and method for screening therapeutic agent for viral infectious disease8 Oct 2026US 2026/0308206 A1Kagoshima University
- A system for identifying microbial growth8 Oct 2026US 2026/0308657 A1Microplate Dx Ltd.
- Screening for host-microbe interactions24 Sep 2026US 2026/0286447 A1Kanvas Biosciences, Inc.
- Phage therapy utilizing a unique cocktail of pseudomonas aeruginosa phages10 Sep 2026US 2026/0263544 A1
- Rapid evaporative ionisation mass spectrometry ("reims") and desorption electrospray ionisation mass spectrometry ("desi-ms") analysis of swabs and biopsy samples10 Sep 2026US 2026/0269206 A1Micromass UK Limited
Most cited
By later US patents
- Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1328US 7,595,048 B2Ono Pharmaceutical Co., Ltd. · 2009
- Interaction trap assay, reagents and uses thereof325US 6,200,759 B1President and Fellows of Harvard College · 2001
- Intraction trap assay, reagents and uses thereof320US 5,925,523 APresident and Fellows of Harvard College · 1999
- Immunopotentiative composition237US 8,728,474 B2Ono Pharmaceutical Co., Ltd. · 2014
- Cell viability detection using electrical measurements228US 6,927,049 B2The Regents of the University of California · 2005